Document Detail

The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
MedLine Citation:
PMID:  17383045     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIMS: We undertook a pilot study to investigate the efficacy and safety of peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed chronic HCV patients awaiting renal transplant. METHODS: Patients received peginterferon alfa-2a 135 microg/week plus ribavirin 200 mg/day for 24 or 48 weeks (genotype non-1 and 1, respectively). The dose of ribavirin was tailored according to plasma concentrations and to haemoglobin levels. Outcomes in treated patients were compared with those of a matched untreated control group. RESULTS: Thirty-five patients received treatment, while 35 served as untreated controls. Thirty patients completed treatment; patients were withdrawn due to transplantation (n=2), severe anaemia (n=1), dermatitis (n=1) and non-response (n=1) resulting in a drop-out rate of 14%. Overall, 34/35 treated patients were HCV RNA negative at week 4 and had undetectable RNA at the end of treatment, compared with none of the untreated controls (ETR 97% vs 0%; p<0.001). Moreover, all achieved sustained virological response after 24 weeks of treatment-free follow-up versus no control patients (SVR 97% vs 0 %; p<0.001). CONCLUSIONS: In this study, we have shown for the first time in a large cohort of patients that HCV-patients on haemodialysis can be treated successfully with peginterferon alfa-2a (40 kDa) plus ribavirin.
Maria Rendina; Antonio Schena; Nicola Maurizio Castellaneta; Francesco Losito; Anna Cinzia Amoruso; Giovanni Stallone; Francesco Paolo Schena; Alfredo Di Leo; Antonio Francavilla
Related Documents :
12900815 - Clinical evaluation of heme iron polypeptide: sustaining a response to rhuepo in hemodi...
8882025 - The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an a...
3392895 - Erythrocytapheresis. a method for rapid extracorporeal elimination of erythrocytes. res...
18978745 - Hsct for fanconi anemia in children: factors that influence early and late results.
25279875 - Screening for connective tissue disease in pulmonary arterial hypertension.
16281095 - A rare diagnosis: testicular dysgenesis with carcinoma in situ detected in a patient wi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-02-05
Journal Detail:
Title:  Journal of hepatology     Volume:  46     ISSN:  0168-8278     ISO Abbreviation:  J. Hepatol.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-10     Completed Date:  2007-08-30     Revised Date:  2008-12-01    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  768-74     Citation Subset:  IM    
Department of Emergency and Organ Transplantation, Section of Gastroenterology, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage*
Drug Therapy, Combination
Follow-Up Studies
Hepacivirus / drug effects,  metabolism
Hepatitis C, Chronic / complications,  drug therapy*,  virology
Injections, Subcutaneous
Interferon Alfa-2a / administration & dosage*
Kidney Failure, Chronic / etiology,  therapy
Kidney Transplantation
Middle Aged
Pilot Projects
Polyethylene Glycols / administration & dosage*
Preoperative Care
RNA, Viral / blood
Renal Dialysis*
Ribavirin / administration & dosage*
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a
Comment In:
J Hepatol. 2008 Sep;49(3):461-2; author reply 462-3   [PMID:  18644649 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA a...
Next Document:  A novel mutation in ferroportin implicated in iron overload.